BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 28158205)

  • 41. LSD1 knockdown reveals novel histone lysine methylation in human breast cancer MCF-7 cells.
    Jin Y; Huo B; Fu X; Cheng Z; Zhu J; Zhang Y; Hao T; Hu X
    Biomed Pharmacother; 2017 Aug; 92():896-904. PubMed ID: 28601046
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Expression, Purification, and Biochemical Analysis of the LSD1/KDM1A Histone Demethylase.
    Laurent B; Shi Y
    Methods Enzymol; 2016; 573():241-59. PubMed ID: 27372756
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Transcriptional regulation of the albumin gene depends on the removal of histone methylation marks by the FAD-dependent monoamine oxidase lysine-specific demethylase 1 in HepG2 human hepatocarcinoma cells.
    Liu D; Zempleni J
    J Nutr; 2014 Jul; 144(7):997-1001. PubMed ID: 24744315
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Heterogeneous Antibody-Based Activity Assay for Lysine Specific Demethylase 1 (LSD1) on a Histone Peptide Substrate.
    Schmitt ML; Ladwein KI; Carlino L; Schulz-Fincke J; Willmann D; Metzger E; Schilcher P; Imhof A; Schüle R; Sippl W; Jung M
    J Biomol Screen; 2014 Jul; 19(6):973-8. PubMed ID: 24687155
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lysine-specific histone demethylase 1 (LSD1): A potential molecular target for tumor therapy.
    Chen Y; Jie W; Yan W; Zhou K; Xiao Y
    Crit Rev Eukaryot Gene Expr; 2012; 22(1):53-9. PubMed ID: 22339659
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nonpeptidic propargylamines as inhibitors of lysine specific demethylase 1 (LSD1) with cellular activity.
    Schmitt ML; Hauser AT; Carlino L; Pippel M; Schulz-Fincke J; Metzger E; Willmann D; Yiu T; Barton M; Schüle R; Sippl W; Jung M
    J Med Chem; 2013 Sep; 56(18):7334-42. PubMed ID: 24007511
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Inhibition of LSD1 sensitizes glioblastoma cells to histone deacetylase inhibitors.
    Singh MM; Manton CA; Bhat KP; Tsai WW; Aldape K; Barton MC; Chandra J
    Neuro Oncol; 2011 Aug; 13(8):894-903. PubMed ID: 21653597
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Structure-based design and discovery of potent and selective lysine-specific demethylase 1 (LSD1) inhibitors.
    Nie Z; Shi L; Lai C; Severin C; Xu J; Del Rosario JR; Stansfield RK; Cho RW; Kanouni T; Veal JM; Stafford JA; Chen YK
    Bioorg Med Chem Lett; 2019 Jan; 29(1):103-106. PubMed ID: 30409536
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Discovery and synthesis of novel indole derivatives-containing 3-methylenedihydrofuran-2(3H)-one as irreversible LSD1 inhibitors.
    Liu HM; Suo FZ; Li XB; You YH; Lv CT; Zheng CX; Zhang GC; Liu YJ; Kang WT; Zheng YC; Xu HW
    Eur J Med Chem; 2019 Aug; 175():357-372. PubMed ID: 31096156
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impairment of prostate cancer cell growth by a selective and reversible lysine-specific demethylase 1 inhibitor.
    Willmann D; Lim S; Wetzel S; Metzger E; Jandausch A; Wilk W; Jung M; Forne I; Imhof A; Janzer A; Kirfel J; Waldmann H; Schüle R; Buettner R
    Int J Cancer; 2012 Dec; 131(11):2704-9. PubMed ID: 22447389
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tranylcypromine and 6-trifluoroethyl thienopyrimidine hybrid as LSD1 inhibitor.
    Wang X; Su M; Li Y; Liu T; Wang Y; Chen Y; Tang L; He YP; Ding X; Yu F; Shen J; Li J; Zhou Y; Chen YL; Xiong B
    Bioorg Med Chem Lett; 2019 Mar; 29(6):844-847. PubMed ID: 30713023
    [TBL] [Abstract][Full Text] [Related]  

  • 52. C-H activation enables a rapid structure-activity relationship study of arylcyclopropyl amines for potent and selective LSD1 inhibitors.
    Miyamura S; Araki M; Ota Y; Itoh Y; Yasuda S; Masuda M; Taniguchi T; Sowa Y; Sakai T; Suzuki T; Itami K; Yamaguchi J
    Org Biomol Chem; 2016 Sep; 14(36):8576-85. PubMed ID: 27548471
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Novel histone demethylase LSD1 inhibitors selectively target cancer cells with pluripotent stem cell properties.
    Wang J; Lu F; Ren Q; Sun H; Xu Z; Lan R; Liu Y; Ward D; Quan J; Ye T; Zhang H
    Cancer Res; 2011 Dec; 71(23):7238-49. PubMed ID: 21975933
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Facile synthesis of substituted trans-2-arylcyclopropylamine inhibitors of the human histone demethylase LSD1 and monoamine oxidases A and B.
    Gooden DM; Schmidt DM; Pollock JA; Kabadi AM; McCafferty DG
    Bioorg Med Chem Lett; 2008 May; 18(10):3047-51. PubMed ID: 18242989
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Inhibitors of enzymes catalyzing modifications to histone lysine residues: structure, function and activity.
    Lillico R; Stesco N; Khorshid Amhad T; Cortes C; Namaka MP; Lakowski TM
    Future Med Chem; 2016 May; 8(8):879-97. PubMed ID: 27173004
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Design, Synthesis, and Evaluation of (2-Aminocyclopropyl)phenyl Derivatives as Novel Positron Emission Tomography Imaging Agents for Lysine-Specific Demethylase 1 in the Brain.
    Hattori Y; Matsuda S; Baba R; Matsumiya K; Iwasaki S; Constantinescu CC; Morley TJ; Carroll VM; Papin C; Gouasmat A; Alagille D; Tamagnan G; Koike T
    J Med Chem; 2021 Apr; 64(7):3780-3793. PubMed ID: 33729758
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Development of the triazole-fused pyrimidine derivatives as highly potent and reversible inhibitors of histone lysine specific demethylase 1 (LSD1/KDM1A).
    Li Z; Ding L; Li Z; Wang Z; Suo F; Shen D; Zhao T; Sun X; Wang J; Liu Y; Ma L; Zhao B; Geng P; Yu B; Zheng Y; Liu H
    Acta Pharm Sin B; 2019 Jul; 9(4):794-808. PubMed ID: 31384539
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Crosstalk between lysine-specific demethylase 1 (LSD1) and histone deacetylases mediates antineoplastic efficacy of HDAC inhibitors in human breast cancer cells.
    Vasilatos SN; Katz TA; Oesterreich S; Wan Y; Davidson NE; Huang Y
    Carcinogenesis; 2013 Jun; 34(6):1196-207. PubMed ID: 23354309
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [1,2,3]Triazolo[4,5-d]pyrimidine derivatives incorporating (thio)urea moiety as a novel scaffold for LSD1 inhibitors.
    Li ZH; Ma JL; Liu GZ; Zhang XH; Qin TT; Ren WH; Zhao TQ; Chen XH; Zhang ZQ
    Eur J Med Chem; 2020 Feb; 187():111989. PubMed ID: 31881456
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Epigenetic regulation of Atrophin1 by lysine-specific demethylase 1 is required for cortical progenitor maintenance.
    Zhang F; Xu D; Yuan L; Sun Y; Xu Z
    Nat Commun; 2014 Dec; 5():5815. PubMed ID: 25519973
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.